Pfizer seeks FDA approval to vaccinate 6-month-old infants — Analysis
If accepted, Pfizer’s vaccine could be the primary out there for American youngsters below the age of 5
Pfizer and BioNTech introduced on Tuesday that they had been in search of approval from the US Meals and Drug Administration (FDA) to vaccinate youngsters as younger as 6 months previous towards Covid-19.
If given approval, youngsters aged six months to 5 years previous would be capable to get vaccinated towards Covid-19 with Pfizer and BioNTech’s vaccine. At the moment, youngsters aged 5 and above are in a position to get vaccinated within the US with Pfizer’s vaccine – although not Moderna and Janssen, that are restricted to over 18s.
Pfizer claimed in a press launch that there was an “pressing public well being want” for youngsters below the age of 5 to get vaccinated towards the coronavirus.
“This software is for authorization of the primary two 3 µg doses of a deliberate three-dose major collection on this age group,” Pfizer defined, including that the corporate was nonetheless awaiting trial information on a 3rd dose for younger youngsters.
“COVID-19 instances and associated hospitalization amongst youngsters have spiked dramatically throughout the USA in the course of the Omicron variant surge,” the press launch claimed, noting that “youngsters below 4 accounted for 3.2% of the overall hospitalizations” a number of weeks in the past.
Pfizer boasted that, if accepted, its vaccine could be the primary out there for youngsters below 5 within the US. In accordance with the CDC, over 80% of Individuals aged 5 and over have obtained not less than one dose of a Covid-19 vaccine. Roughly 67.9% of Individuals over the age of 5 are “totally vaccinated” with two doses of the vaccine.